Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, was $22 million, a decrease of approximately 14% from $25.7 million in 2024 [17] - Gross profit increased to $8.4 million or 38.2% of revenue compared to $8.2 million or 32% of revenue in 2024 [19] - Operating expenses declined by 25% to $28.1 million in 2025 compared to $37.6 million in 2024 [20] - Net loss narrowed by 31% to $19.9 million in 2025 compared to $28.9 million in 2024 [22] Business Line Data and Key Metrics Changes - Revenue from ReWalk Personal Exoskeleton was relatively flat at $8.5 million in 2025 compared to $8.9 million in 2024, with units sold increasing by 22% year-over-year [17] - Revenue from MyoCycle FES bike declined by 50% to $600,000, reflecting a strategic focus on core products [18] - Revenue from AlterG products and services was $12.9 million, an 18% decline from 2024, primarily due to lower international sales [18] Market Data and Key Metrics Changes - Reimbursement coverage for ReWalk expanded to include three largest Medicare Advantage insurers in the U.S., covering over 16 million lives [13] - International distribution efforts accelerated following the receipt of CE mark, with Germany as the primary test market [13] Company Strategy and Development Direction - The company is executing a strategy to build a diversified biomedical innovation company with multiple technology platforms [3] - A strategic transaction with Oramed is expected to strengthen the financial foundation and expand strategic scope [4] - Focus on cash flow positive operations while investing in innovations that will define the future of the company [3][25] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about growth in the core med tech business and improvements in operating expenses [15] - The company is focused on building a strong payer engagement capability to expand patient access and accelerate adoption of technologies [11] Other Important Information - The company plans to increase investment in R&D as new products advance to market, including the upper body exoskeleton [21] - A $3 million loan agreement with Oramed was entered into for additional capital support [23] Q&A Session Questions and Answers Question: How does the Oramed POD technology align with the company's current infrastructure? - Management indicated that the integration of Oramed's technology would drive synergies across med tech and biotech, enhancing the company's decentralized approach to commercialization [27][28] Question: What is the timeline for the upper extremity robotic assistance product? - Management stated that the product could be a 510(k) exempt product, with a timeline of 18-24 months for commercialization [32][33] Question: How should investors view the company's diversification into biotech? - Management emphasized that a diversified portfolio in med tech and biotech is beneficial, providing multiple opportunities for product commercialization [42][43]

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, was $22 million, a decrease of approximately 14% from $25.7 million in 2024 [17] - Gross profit increased to $8.4 million or 38.2% of revenue compared to $8.2 million or 32% of revenue in 2024 [19] - Operating loss narrowed by 33% to $19.7 million in 2025 compared to $29.3 million in 2024 [22] - Net loss narrowed by 31% to $19.9 million in 2025 compared to $28.9 million in 2024 [22] - Operating cash usage reduced by 23% to $16.8 million in 2025 compared to $21.7 million in 2024 [23] Business Line Data and Key Metrics Changes - Revenue from ReWalk Personal Exoskeleton was relatively flat at $8.5 million in 2025 compared to $8.9 million in 2024, with units sold increasing by 22% year-over-year [17] - Revenue from MyoCycle FES bike declined by 50% to $600,000, reflecting a strategic focus on core products [18] - Revenue from AlterG products and services was $12.9 million, an 18% decline from 2024, primarily due to lower international sales [18] Market Data and Key Metrics Changes - Reimbursement coverage for ReWalk expanded to include three largest Medicare Advantage insurers in the U.S., covering over 16 million lives [13] - International distribution efforts accelerated following the receipt of CE mark, with Germany as the primary test market [13] Company Strategy and Development Direction - The company is executing a strategy to build a diversified biomedical innovation company with multiple technology platforms [3] - A strategic transaction with Oramed is expected to strengthen the financial foundation and expand strategic scope [4] - Focus on cash flow positive operations while investing in innovations that will define the future of the company [3][25] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about growth in the core med tech business and improvements in operating expenses [15] - The company is committed to continuous innovation and leveraging advanced robotics and AI technologies [10] Other Important Information - The company plans to increase investment in R&D to advance new products to market, including a recently acquired powered upper body exoskeleton [21] - The company will not provide guidance at this time due to significant transformations and pending agreements [14] Q&A Session Summary Question: How does the Oramed POD technology align with the company's commercial infrastructure? - Management indicated that the integration of Oramed's technology will drive synergies across med tech and biotech, enhancing the company's decentralized approach to commercialization [27][31] Question: What is the timeline for the upper extremity robotic assistance product? - Management expects the product to take 18-24 months to complete, with a low barrier to entry for regulatory approval [32][33] Question: How should investors view the company's diversification into biotech? - Management emphasized that a diversified portfolio in med tech and biotech is beneficial, providing resilience and multiple opportunities for product commercialization [42][43] Question: What drove the additional execution in revenue? - Management attributed the revenue performance to improved understanding of reimbursement pathways and better payer coverage, with expectations for continued growth [49][50]

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, was $22 million, a decrease of approximately 14% from $25.7 million in 2024 [18] - Gross profit increased to $8.4 million or 38.2% of revenue compared to $8.2 million or 32% of revenue in 2024 [20] - Operating loss narrowed by 33% to $19.7 million in 2025 compared to $29.3 million in 2024 [22] - Net loss narrowed by 31% to $19.9 million in 2025 compared to $28.9 million in 2024 [22] - Operating cash usage reduced by 23% to $16.8 million in 2025 compared to $21.7 million in 2024 [23] Business Line Data and Key Metrics Changes - Revenue from ReWalk Personal Exoskeleton was relatively flat at $8.5 million in 2025 compared to $8.9 million in 2024, with units sold increasing by 22% year-over-year [18] - Revenue from MyoCycle FES bike declined by 50% to $600,000, reflecting a strategic focus on core products [19] - Revenue from AlterG products and services was $12.9 million, a decline of 18% from 2024, primarily due to lower international sales [19] Market Data and Key Metrics Changes - ReWalk achieved reimbursement coverage with three largest Medicare Advantage insurers in the U.S., representing over 16 million covered lives [13] - International distribution for ReWalk expanded, with Germany as the primary test market [13] Company Strategy and Development Direction - The company is executing a strategy to build a diversified biomedical innovation company with multiple technology platforms [3] - A strategic transaction with Oramed is expected to strengthen the financial foundation and support growth initiatives [4] - The acquisition of technology from Skelable aims to enhance the upper extremity rehabilitation market [6][9] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about growth in the core med tech business and improvements in operating expenses driving the company toward positive cash flow [16] - The company is focused on expanding reimbursement coverage and building a stronger payer engagement capability [11] Other Important Information - The company will not provide guidance at this time due to significant transformations and pending transactions [15] - The strategic agreement with Oramed is expected to close soon, providing additional capital support [23] Q&A Session Summary Question: How does the Oramed POD technology align with the company's commercial infrastructure? - Management indicated that the integration of Oramed's technology will drive synergies across med tech and biotech, enhancing the company's decentralized approach to commercialization [27] Question: What is the timeline for the upper extremity robotic assistance product? - Management stated that the product could be 510(k) exempt and expects to complete the necessary studies within 18-24 months [31][32] Question: How does the company plan to address competition in the upper extremity market? - Management acknowledged the presence of competitors but emphasized the unique approach and simplicity of their product [36] Question: Can the company quantify the backlog entering 2026? - Management noted that while the pipeline is growing, specific numbers are not available at this time, but there is a focus on the 22% growth in units year-over-year [51]

Core Viewpoint - Lifeward Ltd. has expanded its distribution partnership with SportsMed Products Ltd. to include the United Arab Emirates and the Gulf Cooperation Council region, enhancing the reach of its AlterG product lines [1][2]. Company Overview - Lifeward Ltd. is a global leader in innovative medical technology focused on transforming the lives of individuals with physical limitations or disabilities, with a mission to drive innovation in rehabilitation and recovery [3]. - The company offers a range of products including the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, and has operations in the United States, Israel, and Germany [3]. Partnership Details - The partnership with SportsMed Products Ltd. aims to leverage their established presence in the UK and Ireland, where they have sold over 300 AlterG devices since becoming the exclusive dealer in 2015 [2]. - SportsMed Performance Trading LLC, operating in the GCC, has launched a demo zone in Dubai for customers to experience the latest AlterG NEO+ system [2]. Market Expansion - The expansion into the UAE and GCC is seen as a critical step for Lifeward to enhance the global reach and success of its AlterG product lines [2].

Lifeward (LFWD) Conference Summary Company Overview - **Company**: Lifeward Limited - **Industry**: Medical Devices, specifically focused on rehabilitation technologies such as exoskeletons and functional electrical stimulation devices Key Points and Arguments Future Growth and Positioning - Lifeward has developed leading innovative technologies aimed at fundamentally changing lives, with a focus on commercialization [4][6] - The company has achieved significant milestones, including Medicare coverage for personal exoskeletons, which positions them for future growth [9][31] Product Portfolio - Lifeward's product lineup includes: - **ReWalk**: A personal exoskeleton for restoring functional walking [12][43] - **AlterG**: An antigravity system for rehabilitation [35][38] - **MyoCycle FES**: A functional electrical stimulation bike for therapy [40][41] - **ReStore Exosuit**: A soft exoskeleton primarily for stroke patients [43][44] Market Access and Reimbursement - The company has made strides in reimbursement coverage, with significant contracts established in the U.S. and Germany [29][31] - Lifeward is focusing on expanding into the commercial market and enhancing relationships with workers' compensation [30][32] Market Size and Potential - The total addressable market for ReWalk in the U.S. is approximately 15,000 eligible candidates, with an additional 2,000 in Germany, indicating a substantial growth opportunity [34] - The company is targeting a broader market with its various products, aiming for profitability through market penetration [34][71] Financial Performance and Path to Profitability - Lifeward expects to achieve revenue between $28 million to $30 million for the current year, with a goal of reaching breakeven at $40 million to $45 million in revenue by 2026 [47][71] - The company has improved gross margins through efficient operations and product mix [48][65] Product Development and Innovation - Lifeward has launched new versions of its products, enhancing user experience with features like smoother movement and better control [18][19][21] - Continuous feedback from users has driven product improvements, emphasizing the importance of user experience in rehabilitation technologies [27][28] Industry Dynamics - The medical device industry is fragmented, presenting opportunities for future consolidation as Lifeward continues to grow and integrate its product lines [46][47] - The company is strategically positioned to leverage its clinic presence to drive referrals and enhance product adoption [67][68] Additional Important Information - Lifeward's products are manufactured in various locations, with ReWalk produced in Israel and other products made in the U.S. [72] - The company has navigated tariff concerns effectively, with protocols in place to mitigate potential impacts [72] This summary encapsulates the key insights from the Lifeward conference, highlighting the company's strategic direction, product offerings, market potential, and financial outlook.